The technique, known as auricular point acupressure, or APA, is rooted in auricular therapy, a branch of traditional practice that maps regions of the ear to neurological and somatic pathways involved in pain modulation. In the trial, participants wore tiny vaccaria seeds adhered to predefined auricular points for four weeks and were instructed to press the seeds daily to stimulate the points. The researchers tested two delivery models: a mobile-supported version, called mAPA, in which participants received in-person seed placement and hands-on training reinforced by smartphone instructions and Zoom-based coaching, and a fully virtual version, called vAPA, in which participants learned the technique through standardized instructional videos and remote guidance via a mobile application. Both approaches were designed to be scalable, requiring no ongoing clinical visits once the intervention was underway.

The new report is a prespecified secondary analysis of a three-arm randomized wait-list controlled trial in which 227 adults with moderate or greater CIN were assigned to mAPA, vAPA, or usual care. Because participants in the usual care group were ethically offered APA after their four-week control period, the follow-up phase had no untreated comparison group. The durability analysis therefore focused on the 155 participants who had received one of the two APA variants during the initial randomized phase—80 in the mAPA group and 75 in the vAPA group—and tracked their symptom trajectories at one, two, and three months after the intervention ended. All participants had received neurotoxic chemotherapy and reported pain, numbness, or tingling of at least four on an eleven-point scale at study entry.

The primary outcome was symptom severity measured with an individualized composite outcome, or ICO, derived from the Modified Brief Pain Inventory–Chemotherapy-Induced Neuropathy instrument. For each participant, the ICO captured the single worst symptom-location combination at baseline, providing a personalized anchor for tracking change. The secondary outcome was CIN interference, which measures how much neuropathy disrupts daily activities, mood, walking, work, relationships, sleep, and enjoyment of life. Both scales run from zero to ten, which makes the magnitude of change clinically interpretable: a one- to three-point reduction on such scales is generally considered meaningful for patients.

The results were striking in their consistency. In the mAPA group, ICO scores fell by 3.10 points at one month, 3.36 points at two months, and 3.61 points at three months relative to baseline, with all comparisons reaching statistical significance at p less than 0.001. The vAPA group showed nearly parallel improvements, with reductions of 2.88, 2.90, and 3.21 points at the same time points. Interference scores followed the same pattern, dropping by roughly 1.2 to 1.6 points across follow-up in both groups. Crucially, there was no evidence of symptom worsening at any point after treatment ended, and numerical improvements actually continued to accrue over time, particularly among participants receiving the mobile-supported version. Sensitivity analyses using complete-case data without imputation confirmed the same patterns.

Statistically, the team used generalized estimating equations to account for the correlation among repeated measurements within individuals, and addressed missing data with multilevel multiple imputation that incorporated baseline characteristics and outcome variables. This matters because attrition was substantial, especially in the virtual arm: follow-up completion at one, two, and three months was 62.5, 51.3, and 48.8 percent for mAPA but only 34.7, 30.7, and 25.3 percent for vAPA. Participants with missing data had similar baseline symptom severity to those retained, which offers some reassurance, but the authors are candid that the heavy reliance on imputed values warrants cautious interpretation of the precision of the estimates.

The durability question is scientifically important for a specific reason. In nonpharmacologic and behavioral interventions, improvements measured immediately after treatment can partly reflect expectancy effects, attention, or the novelty of engagement rather than a genuine therapeutic signal. By showing that symptom reductions were maintained—and even deepened—months after the seeds came off and the coaching stopped, the study provides evidence that the benefit was not merely a transient placebo response. The findings also align with a growing literature: a separate randomized trial of APA for chronic low back pain in older adults found benefits maintained up to six months, and auricular acupressure studies in diabetic peripheral neuropathy, a condition sharing many symptoms with CIN, have reported persistent reductions in neuropathic pain and improvements in quality of life.

The clinical context makes these results especially compelling. Current guidelines identify duloxetine as the only pharmacologic therapy with sufficient evidence for painful CIN, and even its benefits are modest, leaving many patients with residual symptoms. Recent systematic reviews conclude that evidence supporting most other pharmacologic and nonpharmacologic interventions remains limited or inconsistent. Against that backdrop, APA stands out as a low-risk, noninvasive, and inexpensive option that patients can administer themselves at home. The fact that both the in-person-supported and the fully virtual formats produced sustained improvements suggests the therapy could be scaled to reach survivors who lack access to specialty supportive care, an increasingly relevant consideration as digital health expands across cancer survivorship.

Yet the study’s limitations temper enthusiasm. Without an untreated concurrent control group during follow-up, the maintained improvements cannot be definitively attributed to APA rather than natural recovery, regression to the mean, or expectancy effects. Adherence to the technique after the intervention was not systematically monitored, so some participants may have continued practicing or adopted other strategies. The three-month follow-up window leaves open whether benefits persist longer or whether booster treatments would be needed. Outcomes were primarily patient-reported, so the study cannot confirm whether subjective improvements corresponded to measurable neurological changes, although the parent trial collected objective sensory testing that may inform future analyses. Attrition was also higher in the virtual arm, and the authors suggest that hybrid models combining remote delivery with brief human support may better sustain engagement.

Even with those caveats, the study represents a meaningful step toward addressing one of oncology’s most persistent unmet needs. Roughly a third of colorectal cancer survivors treated with oxaliplatin still experience neuropathy five years after treatment, with minimal spontaneous improvement, underscoring how desperately durable solutions are needed. A four-week course of ear seeds, pressed daily by the patient’s own fingers, that keeps working for at least three months afterward is an appealing proposition precisely because it is so simple. Larger trials with longer follow-up, untreated comparison groups, and objective outcome measures are now required to confirm the effect and define APA’s place in survivorship care. But if the findings hold, a technique that costs pennies and requires no prescription could become a genuine tool for the millions of survivors living with chemotherapy’s longest shadow.

Subject of Research: Sustained effects of auricular point acupressure on chemotherapy-induced peripheral neuropathy in cancer survivors

Article Title: Sustained effects of auricular point acupressure on chemotherapy-induced neuropathy: a randomized controlled trial follow-up study

Article References: Lukkahatai, N., Jiang, Y., Zhang, J., Kawi, J., Wu, H., Wang, H., Campbell, C. M., Thrul, J., Abdi, S., Hacker, E. D., Johnson, C. M., & Smith, T. J. (2026). Sustained effects of auricular point acupressure on chemotherapy-induced neuropathy: a randomized controlled trial follow-up study. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02104-3

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02104-3

Keywords: chemotherapy-induced neuropathy, auricular point acupressure, acupressure, auriculotherapy, randomized controlled trial, cancer survivorship, neuropathic pain, nonpharmacologic intervention, self-management, digital health, ear seeds, symptom management

The team conducted a scoping review, a study design intended to chart the breadth and quality of existing evidence rather than pool it into a single statistical estimate. The researchers searched PubMed, EBSCO, CINAHL, Ovid and Google Scholar for studies published between May 2012 and February 2025, structuring their search around the PICO framework—population, intervention, comparison, outcome—and assessed the methodological rigor of each study using the quality assessment tools developed by the United States National Heart, Lung, and Blood Institute. The haul amounted to 35 individual investigations: 27 randomized controlled trials, three randomized pilot studies, four pre-post studies and one case series. That breadth matters, because perineal pain is not a niche complaint. Assisted deliveries, episiotomies and perineal lacerations all increase both the intensity of pain and the amount of medication women need afterward, making effective conservative options a genuine public health question.

The clearest signal in the review came from an almost old-fashioned remedy. Eight studies supported cold therapy—ice packs, cold gel pads and similar applications—for short-term relief of perineal pain. The technique is physiologically plausible: cooling the tissue slows local nerve conduction, reduces swelling and dampens inflammatory signaling in the damaged perineal wound. The catch, the authors note, is that the studies used markedly different protocols, varying in how long the cold was applied, how often, and with what devices. Without standardized treatment regimens, clinicians have little guidance on how to translate the positive findings into practice, even though the direction of the evidence is consistent and the intervention carries essentially no pharmacological risk to a nursing mother.

Light-based therapies produced a far more skeptical verdict. Five studies examined light therapy, split between low-level laser therapy and far-infrared radiation, and most showed no superiority over placebo or no treatment. Low-level laser therapy delivers non-thermal red and near-infrared light intended to stimulate cellular repair, while far-infrared devices emit gentle radiant heat; neither convincingly outperformed sham treatment in the trials reviewed. This stands in contrast to the enthusiasm that light-based wound-healing devices sometimes attract, and it underscores a recurring theme of the review: plausible mechanisms do not guarantee clinical benefit, and rigorous randomized comparisons frequently deflate early promise.

Electricity fared considerably better. Four trials of transcutaneous electrical nerve stimulation, or TENS, showed the technique’s superiority over placebo despite varying stimulation protocols. TENS works through electrodes placed on the skin that deliver low-voltage electrical pulses, thought to activate inhibitory pain pathways in the spinal cord—the gate-control mechanism that competes with pain signals before they reach consciousness. Trials tested both high-frequency and low-frequency stimulation, and while protocols were again inconsistent, the consistent finding across studies was meaningful pain reduction. For women reluctant to take any systemic drug in the early postpartum days, a wearable electrical device offers an appealing, drug-free adjunct or alternative.

Radiofrequency therapy, a less familiar option to most patients, also emerged as a candidate worth watching. Two randomized controlled trials of radiofrequency treatment reported reduced perineal pain and discomfort in certain positions. The reviewed studies included capacitive and resistive energy transfer systems, which heat deeper tissue layers to promote circulation and healing. The evidence base is thin—just two trials—but both pointed in the same direction, prompting the authors to place radiofrequency alongside cold therapy and TENS among the most promising conservative treatments. One additional study found therapeutic ultrasound delivered with gel pads more effective than gel pads alone or laser therapy, adding a further physical modality to the shortlist, though a single trial is far from definitive.

Temperature-based care during and after labor received mixed marks. Two studies found that heat therapy applied during labor was effective for short-term pain relief, and two observational studies examined water immersion, but the latter were judged to be of low quality, leaving their findings uncertain. One study that combined cold application, heat application and pelvic floor muscle training showed significant benefits lasting up to seven days after delivery, suggesting that multi-component conservative care may outperform any single technique. Intriguingly, the reviewers found that no study has yet tested pelvic floor muscle training on its own for postpartum perineal pain relief—an conspicuous gap, given how widely the exercises are prescribed for pelvic floor recovery after childbirth.

The review was less kind to hands-on and needle-based traditions. A single study of manual therapy produced results the authors described as unclear, and its quality was rated low. Seven trials of acupuncture and acupressure—needle stimulation and finger pressure at defined points, respectively—were of poor to fair methodological quality, with mixed findings on whether the techniques reduced pain or the need for pain medication. With no high-quality randomized evidence to lean on, the reviewers declined to endorse these approaches, a sobering conclusion for a family of therapies often assumed to be well supported. Similarly, the single study touching on osteopathic manipulative treatment left the question of its value essentially open.

The methodological weaknesses that run through the evidence base are as important as any individual result. Only a minority of the 35 studies were fully powered randomized controlled trials, blinding is inherently difficult when the treatment involves visible ice packs or electrical devices, and outcome measures varied from visual analogue and numerical rating scales to composite wound-healing scores such as the REEDA scale and questionnaires on postpartum comfort and sexual function. The authors’ conclusion is deliberately cautious: the evidence supports cold therapy, TENS and radiofrequency as emerging options, but the limited number of robust studies means clinicians and patients should interpret even the positive findings carefully until larger, protocol-standardized trials are completed.

Still, the practical implications are significant for a condition that touches nearly every vaginal delivery. Perineal pain in the first weeks after birth interferes with breastfeeding, infant care, sleep, mobility and early sexual recovery, and up to 37 percent of affected women rate their pain as moderate to severe even while taking conventional analgesics. A structured, evidence-informed toolkit of cooling, electrical stimulation and possibly radiofrequency could meaningfully reduce reliance on opioids and other systemic drugs at a time when many mothers are anxious about medication passing into breast milk. The Gdańsk team’s review does not declare any of these treatments a cure, but it does something arguably more useful: it separates the therapies with converging randomized evidence from those riding on hype, and it lays out exactly where the next generation of trials should focus. For postpartum women and the clinicians who care for them, the message is that sometimes the most effective medicine for childbirth’s most common overlooked pain may be found not in the pharmacy, but in the freezer, the physiotherapy suite and the low-voltage electrode.

Subject of Research: Non-pharmacological management of postpartum perineal pain

Article Title: When analgesics are not enough for postpartum perineal pain—a scoping review of the non-pharmacological, conservative therapies

Article References: Wojtas, J., Sotomska, Z., Pietrzak, J., Waldman, A., Wydra, D., & Grzybowska, M. E. (2026). When analgesics are not enough for postpartum perineal pain—a scoping review of the non-pharmacological, conservative therapies. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05544-7

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05544-7

Keywords: postpartum perineal pain, cold therapy, TENS, radiofrequency, scoping review, pain management, non-pharmacological therapies, low-level laser therapy, acupuncture, acupressure, pelvic floor, childbirth recovery